Endocrinology and Aging

  • Hosam K. Kamel
  • John E. Morley


In 1889 C.E. Brown-Sequard, a noted French scientist, claimed that a water-soluble extract of dog testes gave him an “astonishing degree of rejuvenation” and improved his long-standing problems with impotence.1 Although we now know that there was minimal testosterone or other sex steroids in this water-soluble extract, the link between hormones and aging was clearly postulated. Over the past century our understanding of hormonal changes with age and the effect of hormonal repletion in elderly individuals has increased dramatically. It is now well established that aging is associated with a host of changes in the endocrine system (Table 20.1). At present, it is not completely clear whether these age-related changes aggravate the alterations in various biologic functions that accompany aging or are compensatory events that minimize tissue damage and conserve organ vitality. This chapter reviews the age-related changes in the endocrine system.


Luteinizing Hormone Estrogen Replacement Therapy Subclinical Hypothyroidism Multinodular Goiter Dehydroepiandrosterone Sulfate 


Unable to display preview. Download preview PDF.

Unable to display preview. Download preview PDF.


  1. 1.
    Brown-Sequard CE. Du role physiologique et therapeutique d’un sue extrait de testicules d’animaux d’apres nombre de faits observes chez l’homme. Arch Physiol Norm Pathol 1889;1:739–746.Google Scholar
  2. 2.
    Gregerman RI, Davis PJ. Effects of intrinsic and extrinsic variables on thyroid economy. In: Werner SC, Ingbar SH (eds) The Thyroid, 4th ed. Harper & Row: Hagerstown, MD, 1978:223.Google Scholar
  3. 3.
    Hegedus L, Perrild H, Poulsen LR, et al. The determination of thyroid volume by ultrasound and its relationship to body weight, age, sex in normal subjects. J Clin Endocrinol Metab 1983;56:260.PubMedCrossRefGoogle Scholar
  4. 4.
    Gambert SR. Endocrinology and aging. In: Reichel W (ed) Care of The Elderly, 4th ed. Williams & Wilkins: Baltimore, 1995:365–372.Google Scholar
  5. 5.
    Mooradian AD, Morley JE, Korenman SG. Endocrinology in aging. Dis Mon 1998;34:398–461.CrossRefGoogle Scholar
  6. 6.
    Kaiser FE. Variability of response to thyroid-releasing hormone in normal elderly. Age Ageing 1987;16:345–354.PubMedCrossRefGoogle Scholar
  7. 7.
    Sawin CT, Geller A, Kaplan MM, et al. Low serum thyrotropin (thyroid-stimulating hormone) in older persons without hyperthyroidism. Arch Intern Med 1991;151:165.PubMedCrossRefGoogle Scholar
  8. 8.
    Meyers B, Gionet M, Abreau C, et al. Iodine intake probably affects the incidence of hypothyroidism and Hashimoto’s thyroiditis in elderly women [abstract]. J Nucl Med 1986;27:909.Google Scholar
  9. 9.
    Okamoto T, Fujimoto Y, Obara T, et al. Retrospective analysis of prognostic factors affecting the thyroid function status after subtotal thyroidectomy for Graves’ disease. World J Surg 1992;16:690.PubMedCrossRefGoogle Scholar
  10. 10.
    Davis PJ, Davis FB. Hyperthyroidism in patients over the age of 60 years: clinical features in 85 patients. Medicine 1974;53:161–181.PubMedCrossRefGoogle Scholar
  11. 11.
    Cropper CFJ. Hypothyroidism in psycho-geriatric patients: ankle jerk reaction time as a screening technique. Gerontol Clin 1973;15:15–24.CrossRefGoogle Scholar
  12. 12.
    Lioyd WH, Goldbeg IJL. Incidence of hypothyroidism in the elderly. Br Med J 1961;2:1256.CrossRefGoogle Scholar
  13. 13.
    Morley JE. The aging endocrine system. Postgrad Med 1983;73:107.PubMedGoogle Scholar
  14. 14.
    Barnett DB, Greenfield AA, Howlett PJ, et al. Discriminant value of thyroid function tests. Br Med J 1973;2:144.PubMedCrossRefGoogle Scholar
  15. 15.
    Sawin CT. Subclinical hypothyroidism in older persons. Clin Geriatr Med 1995;11:231–238.PubMedGoogle Scholar
  16. 16.
    Bagchi N, Brown TR, Parish RF. Thyroid dysfunction in adults over age 55 years: a study in an urban US community. Arch Intern Med 1990;150:785.PubMedCrossRefGoogle Scholar
  17. 17.
    Parle JV, Franklyn JA, Cross KW. Prevalence and follow-up of abnormal thyrotropin (TSH) concentrations in the elderly in the United Kingdom. Clin Endocrinol (Oxf) 1991;34:77.CrossRefGoogle Scholar
  18. 18.
    Sawin CT, Chopra D, Azizi F, et al. The aging thyroid increased prevalence of elevated serum thyrotropin levels in the elderly. JAMA 1979;242:247.PubMedCrossRefGoogle Scholar
  19. 19.
    Ridgway EC, Cooper DS, Walker H, et al. Peripheral responses to thyroid hormone before and after L-thyroxine therapy in patients with subclinical hypothyroidism. J Clin Endocrinol Metab 1981;52:1238–1242.CrossRefGoogle Scholar
  20. 20.
    Rosenbaum RL, Barzel US. Levothyroxine replacement dose for primary hypothyroidism decreases with age. Ann Intern Med 1982;144:175.Google Scholar
  21. 21.
    Tunbridge WMG, Evered DC, Hall R, et al. The spectrum of thyroid disease in a community: the Wickham survey. Clin Endocrinol (Oxf) 1997;7:481.CrossRefGoogle Scholar
  22. 22.
    Davis PJ, Davis FB. Hyperthyroidism in patients over the age of 60 years: clinical features in 85 patients. Medicine 1974;53:161–181.PubMedCrossRefGoogle Scholar
  23. 23.
    Dabon-Almirante CM, Surks M. Clinical and laboratory diagnosis of thyrotoxicosis. Endocrinol Metab Clin North Am 1998;27:25–35.PubMedCrossRefGoogle Scholar
  24. 24.
    Nicoloff JT, Spencer CA. Clinical review. 12. The use and misuse of the sensitive thyrotropin assay. J Clin Endocrinol Metab 1990;71:553.PubMedCrossRefGoogle Scholar
  25. 25.
    Gambert SR. Endocrine and metabolic disorders. In: Reubin D, et al. (eds) Geriatric Review Syllabus, 3rd ed. AGS, Washington DC 1996:296–303.Google Scholar
  26. 26.
    Mooradian AD, Allan CR, Khalil MF, et al. Anaplastic transformation of thyroid cancer: report of two cases and review of the literature. J Surg Oncol 1983;23:95–98.PubMedCrossRefGoogle Scholar
  27. 27.
    Bullamore JR, Gallagher JC, Wilkinson R, et al. Effect of age on calcium absorption. Lancet 1970;2:535–537.PubMedCrossRefGoogle Scholar
  28. 28.
    Armbrecht HJ. Calcium, vitamin D, and aging. In: Morley JE, Korenman SG (eds) Endocrinology and Metabolism in the Elderly. Blackwell Scientific: Boston, 1992:170–182.Google Scholar
  29. 29.
    Lund B, Clausen N, Laund B, et al. Age-dependent variations in serum 1,25-dihydroxyvitamin D in childhood. Acta Endocrinol (Copenh) 1980;94:426–429.Google Scholar
  30. 30.
    Tsai KS, Heath H, Kumar R, et al. Impaired vitamin D metabolism with aging in women: possible role in pathogenesis of senile osteoporosis. J Clin Invest 1984;73: 1668–1672.PubMedCrossRefGoogle Scholar
  31. 31.
    Armbrecht H, Zenser T, Davis B. Effect of age on the conversion of 25(OH)D to l,25-(OH)2 D by kidney of rat. J Clin Invest 1980;66:1118.PubMedCrossRefGoogle Scholar
  32. 32.
    Elbeling PR, Yergey AL, Viera NE, et al. Influence of age on effects of endogenous l,25(OH)2D on calcium absorption in normal women. Calcif Tissue Int 1994;55: 330–334.CrossRefGoogle Scholar
  33. 33.
    Chapuy M-C, Durr F, Chapuy P. Age-related changes in parathyroid hormone and 25-hydroxycholecaciferol levels. J Gerontol 1983;38:19–22.PubMedCrossRefGoogle Scholar
  34. 34.
    Clemems TL, Zhou X-Y, Myles M, et al. Serum vitamin D2 and vitamin D3 metabolite concentrations and absorption of vitamin D2 in elderly subjects. J Clin Endocrinol Metab 1986;63:656–660.CrossRefGoogle Scholar
  35. 35.
    Goldray D, Mizzrahi-Sasson E, Merdler C, et al. Vitamin D deficiency in elderly patients in a general hospital. J Am Geriatr Soc 1989;37:589–592.PubMedGoogle Scholar
  36. 36.
    Bullamore JR, Gallagher JC, Wilkinson R, et al. Effect of age on calcium absorption. Lancet 1970;2:535–537.PubMedCrossRefGoogle Scholar
  37. 37.
    Maclaughlin J, Holick MJ. Aging decreases the capacity of human skin to produce vitamin D. J Clin Invest 1985;76: 1536–1538.PubMedCrossRefGoogle Scholar
  38. 38.
    Kamel H. Primary hyperparathyroidim: clinical presentation and diagnosis. Clin Geriatr 1997;5(3):72–77.Google Scholar
  39. 39.
    Lyles KW. Hyperparathyroidism and Paget’s disease of bone. In: Hazzard WR, et al (eds) Principles of Geriatric Medicine and Gerontology. pp. 1085–1096, McGraw-Hill: New York, 1998:1085–1096.Google Scholar
  40. 40.
    Bilezikian JP, Silverberg SJ, Horwitz MJ. Clinical presentation of primary hyperparathyoidism. In: Bilezikian JP, Marcus R, Levine MA (eds) The Parathyroids. Raven: New York, 1994:457–469.Google Scholar
  41. 41.
    Chigot J, Menagaux F, Achrafi H. Should primary hyperparathyoidism be treated surgically in elderly patients older than 75 years. Surgery 1995;117:397–401.PubMedCrossRefGoogle Scholar
  42. 42.
    Whitman ED, Norton JA. Endocrine surgical diseases of elderly patients. Surg Clin North Am 1994;74:127–144.PubMedGoogle Scholar
  43. 43.
    Bondenson AG, Bondenson L, Thompson NW. Hyper-parathyroidsm after treatment with radioactive iodine: not only a coincidence? Surgery 1989;106:1025–1027.Google Scholar
  44. 44.
    Holick MF, Krane SM, Potts JT. Disorders of bone and mineral metabolism. In: Isselbacher KJ, et al. (eds) Harrison’s Principles of Internal Medicine, 13th ed. McGraw-Hill: New York, 1994:2137–2171.Google Scholar
  45. 45.
    Bilezikian JP, Silverberg SJ, Shane E, et al. Characterization and evaluation of asymptomatic primary hyperparathyroidism. J Bone Miner Res 1991;4:283–291.Google Scholar
  46. 46.
    Kamel H. Primary hyperparathyroidism: management. Clin Geriatr 1997;5(6):71–81.Google Scholar
  47. 47.
    Grey AB, Stapleton JP, Evans MC, Tatnell MA, Reid IR et al. Effects of hormone replacement therapy on bone mineral density in postmenopausal women with mild primary hyperparathyoidism. Ann Intern Med 1996;125: 360–368.PubMedCrossRefGoogle Scholar
  48. 48.
    Norton JA. Controversies and advances in primary hyperparathyroidism. Ann Surg 1992;215:297.PubMedCrossRefGoogle Scholar
  49. 49.
    Norton JA, Brennan MF, Well SA. Surgical management of hyperparathyroidism. In: Bilezikian JP, Marcus R, Levine MA (eds) The Parathyroids. Raven: New York, 1994:531–551.Google Scholar
  50. 50.
    Report of a WHO study group: assessment of fracture risk and its application to screening for postmenopausal osteoporosis. WHO Techn Rep Ser 1994;843:3–5.Google Scholar
  51. 51.
    Riggs BL. Osteoporosis. In: Wyngaarden JB, Smith LH, Bennet JC (eds) Cecil Textbook of Medicine, 19th ed. Saunders: Philadelphia, 1992:1426–1431.Google Scholar
  52. 52.
    Kamel HK. Osteoporosis and aging: etiology and current diagnostic strategies. Ann Long Term Care 1998;6:352–357.Google Scholar
  53. 53.
    Beatriz JE, Perry M III. Age-related osteoporosis. Clin Geriatr Med 1994;10:575–587.Google Scholar
  54. 54.
    Rosen C, Kessenich CR. The pathophysiology and treatment of postmenopausal osteoporosis. Endocrinol Metab Clin North Am 1997;26:295–311.PubMedCrossRefGoogle Scholar
  55. 55.
    Passeri G, Girasole G, Jilka RL, Manalagas SC. Increased interleukin-6 production by murine bone marrow and bone cells after estrogen withdrawal. Endocrinology 1993;133:295–311.CrossRefGoogle Scholar
  56. 56.
    Girasole G, Passeri G, Jilka RL, et al. Interleukin-11: a new cytokine critical for osteoclast development. J Clin Invest 1994;93:1516–1524.PubMedCrossRefGoogle Scholar
  57. 57.
    Bellido T, Stahl N, Farruggella TJ, et al. Detection of receptors for interleukin-6, interleukin-11, leukemia inhibitory factor, oncostatin M, and ciliary neutrophilic factor in bone marrow stromal/osteoclastic cells. J Clin Invest 1996;97: 431–437.PubMedCrossRefGoogle Scholar
  58. 58.
    World Health Organization. Assessment of Fracture Risk and Its Application to Screening for Postmenoapusal Osteoporosis. WHO: Geneva, 1994. Nical Report Series 843.Google Scholar
  59. 59.
    Cummings SR, Black DM, Nevitt MC, et al. Bone density at various sites for prediction of hip fractures: the study of the osteoporotic fracture research group. Lancet 1993;341: 72–85.PubMedCrossRefGoogle Scholar
  60. 60.
    Bettica P, Taylor AK, Talbot J, et al. Clinical performance of galactosyl hydroxylisine, pyridinoline, and deoxy-pyridoniline in postmenopausal osteoporosis. J Clin Endocrinol Metab 1996;81:542–546.PubMedCrossRefGoogle Scholar
  61. 61.
    Markers of bone resorption predict hip fracture in elderly women: the EPIDOS prospective study. J Bone Miner Res 1996;11:1531–1538.Google Scholar
  62. 62.
    Kamel HK. Pharmacological management of osteoporosis: current trends and future prospects. Ann Long Term Care 1998;6:382–388.Google Scholar
  63. 63.
    Pedersen-Bjerggard K, Tonnesen M. Sex hormone analysis. II. The excretion of sexual hormones by normal males, impotent males, polyathritics, and prostitics. Acta Med Scand 1948;213:284–297.Google Scholar
  64. 64.
    Plymate SR, Tenver JS, Bremner WJ, Circadian variation in testosterone, sex hormone-binding globulin, and calculated non-sex hormone-binding globulin bound testosterone in healthy young and elderly men. J Androl 1989;10: 366.PubMedGoogle Scholar
  65. 65.
    Morley JE, Kaiser FE. Hypogonadism in the elderly man. Adv Endocrinol Metab 1993;4:241–262.Google Scholar
  66. 66.
    Gray A, Feldman HA, Mckenlay JB, et al. Age, disease and changing sex hormone levels in middle-aged men: results of the Massachusetts Male Aging Study. J Clin Endocrinol Metab 1991;73:1016–1025.PubMedCrossRefGoogle Scholar
  67. 67.
    Korenman SG, Morley JE, Mooradian AD, et al. Secondary hypogonadism in older men: its relationship to impotence. J Clin Endocrinol Metab 1990;71:963–969.PubMedCrossRefGoogle Scholar
  68. 68.
    Morley JE, Kaiser FE. Hypogonadism in the elderly man. Adv Endocrinol Metab 1993;4:241.Google Scholar
  69. 69.
    Plymate SR, Tenover JS, Bremner WJ. Circadian variation in testosterone, sex hormone binding globulin and calculated non-sex-hormone binding globulin bound testosterone in healthy young and elderly men. J Androl 1989; 10:366–371.PubMedGoogle Scholar
  70. 70.
    Kaiser FE, Morley FE. Gonadotropins, testosterone, and the aging male: neurobiology of aging. Horm Res 1995;43 (l–3):25–28.Google Scholar
  71. 71.
    Baker HWG, Brenner WJ, Burger HG, et al. Testicular control of follicle stimulating hormone secretion. Recent Prog Horm Res 1976;32:429.PubMedGoogle Scholar
  72. 72.
    Rubens RM, Dhont M, Vermeulen A. Further studies on Leydig cell function in old age. J Clin Endocrinol Metab 1974;39:40.PubMedCrossRefGoogle Scholar
  73. 73.
    Stearns EL, MacDonald JA, Kaufman BJ, et al. Declining testicular function with age, hormonal and clinical correlates. Am J Med 1974;57:761.PubMedCrossRefGoogle Scholar
  74. 74.
    Zummoff B, Strain GW, Kream J. Age variation of the 24-hour mean plasma concentrations of androgens, estrogens and gonadotropins in normal adult men. J Clin Endocrinol Metab 1982;54:534.CrossRefGoogle Scholar
  75. 75.
    Korenman SG, Morley JE, Mooradian AD, et al. Secondary hypogonadism in older men: its relation to impotence. J Clin Endocrinol Metab 1990;71:963–969.PubMedCrossRefGoogle Scholar
  76. 76.
    Morley JE, Kaiser FE, Sih R, et al. Testosterone and frailty. Clin Geriatr Med 1997;13:685–695.PubMedGoogle Scholar
  77. 77.
    Harman SM, Tsitouras PD, Costa PT, et al. Reproductive hormones in aging men. II. Basal pituitary gonadotropins and gonadotropin responses to luteinizing hormone-releasing hormone. J Clin Endocrinol Metab 1982;54:547.PubMedCrossRefGoogle Scholar
  78. 78.
    Ceda GP, Enti L, Cerseini G, et al. The effects of aging on the secretion of the common alpha-subunit of the glycoprotein hormones in men. J Am Geriatr Soc 1991;39:353.PubMedGoogle Scholar
  79. 79.
    Pontiroli AE, Ruga S, Maffi P, et al. Pituitary reserve after repeated administration of releasing hormones in young and in elderly men: reproducibility on different days. J Endocrinol Invest 1992;15:559.PubMedGoogle Scholar
  80. 80.
    Winters SJ, Troen P. Episodic luteinizing hormone (LH) secretion and the response of LH and follicle-stimulating hormone to the LH-releasing hormone in aged men: evidence for coexistent primary testicular insufficiency and an impairment in gonadotropin secretion. J Clin Endocrinol Metab 1982;55:560.PubMedCrossRefGoogle Scholar
  81. 81.
    Winters SJ, Sherins RJ, Troen P. The gonadotropin-suppressive activity of androgen is increased in the elderly men. Metabolism 1984;33:1052–1059.PubMedCrossRefGoogle Scholar
  82. 82.
    Kamel H, Kaiser FE, Morley JE. Erectile dysfunction (impotence). In: Hazzard W, et al (eds) Principles of Geriatric Medicine and Gerontology, 4th ed. McGraw-Hill: New York, 1998:1585–1594.Google Scholar
  83. 83.
    Tenover JS. Effects of testosterone supplementation in the aging male. J Clin Endocrinol Metab 1992;75:1092–1098.PubMedCrossRefGoogle Scholar
  84. 84.
    Reid IR, Wattie DJ, Evans MC, et al. Testosterone therapy in glucocorticoid-treated men. Arch Intern Med 1996;156: 1173–1177.PubMedCrossRefGoogle Scholar
  85. 85.
    Morley JE, Perry HM III, Kaiser FE, et al. Longitudinal changes in testosterone luteinizing hormone and follicle stimulating hormone in healthy older males. Metabolism 1997;46:410–414.PubMedCrossRefGoogle Scholar
  86. 86.
    Sih R, Morley JE, Kaiser FE, et al. Testosterone replacement in older hypogonadal men: a 12 month randomized controlled trial. J Clin Endocrinol Metab 1997;82:1661–1667.PubMedCrossRefGoogle Scholar
  87. 87.
    Jankowsky JS, Oviatt SK, Orwoll ES. Testosterone influences spatial cognition in older men. Behav Neurosci 1994;108:325–332.CrossRefGoogle Scholar
  88. 88.
    Watson RR, Huls A, Araghinikuam M, Chung S. Dehy-droepiandrosterone and diseases of aging. Drugs Aging 1996;9:274–291.PubMedCrossRefGoogle Scholar
  89. 89.
    Vermeulen A. Adrenal Androgens. Raven: New York, 1980:207–217.Google Scholar
  90. 90.
    Orentreich N, Brind JL, Vogelman JH, Andres R, Baldwin H. Long-term longitudinal measurements of plasma dehydroepiandrosterone sulfate in normal men. J Clin Endocrinol Metab 1992;75:1002–1004.PubMedCrossRefGoogle Scholar
  91. 91.
    Morley JE, Kaiser F, Raum WJ, et al. Potentially predictive and manipulable blood serum correlates of aging in the healthy human male: progressive decreases in bioavail-able testosterone, dehydroepiandrosterone sulfate. Proc Natl Acad Sci USA 1997;94:7537–7542.PubMedCrossRefGoogle Scholar
  92. 92.
    Liu CH, Laughlin GA, Fischer UG, Yen SS. Marked attenuation of ultradian and circadian rhythms of dehydroepiandrosterone in postmenopausal women: evidence for a reduced 17,20-desmolase enzymatic activity. J Clin Endocrinol Metab 1990;71:900–906.PubMedCrossRefGoogle Scholar
  93. 93.
    Vermeulen A. Dehydroepiandrosterone sulfate and aging. Ann NY Acad Sci 1995;774:121–127.PubMedCrossRefGoogle Scholar
  94. 94.
    Barrett-Connor E, Khaw KT, Yen SS. A prospective study of dehydroepiandrosterone sulfate, mortality, and cardiovascular disease. N Engl J Med 1986;315:1519–1524.PubMedCrossRefGoogle Scholar
  95. 95.
    Helzouer KJ, Gordon GB, Alberg AJ, Bush TL, Comstock GW. Relationship of prediagnostic serum levels of dehydroepiandrosterone and dehydroepiandrosterone sulfate to the risk of developing premenopausal breast cancer. Cancer Res 1992;52:1–4.Google Scholar
  96. 96.
    Gordon GB, Helzouer KJ, Alberg AJ, Comstock GW. Serum levels of dehydroepiandrosterone and dehydroepiandrosterone sulfate and the risk of developing gastric cancer. Cancer Epidemiol Biomarkers Prev 1993;2:33–35.PubMedGoogle Scholar
  97. 97.
    Szathmari M, Szucs J, Feher T, Hollo I. Dehydroepiandrosterone sulfate and bone mineral density. Osteoporosis Int 1994;4:84–88.CrossRefGoogle Scholar
  98. 98.
    Jesse RL, Lesser K, Eich DM, et al. Dehydroepiandrosterone inhibits human platelet aggregation in vitro and in vivo. Ann NY Acad Sci 1995;774:281–290.PubMedCrossRefGoogle Scholar
  99. 99.
    Beer NA, Jakubowicz DJ, Matt DW, Beer RM, Nestler JE. Dehydroepiandrosterone reduces plasma plasminogen activator inhibitor type 1 and tissue plasminogen activator antigen in men. Am J Med Sci 1996;311:205–210.PubMedCrossRefGoogle Scholar
  100. 100.
    Yen SSC, Morales AJ, Khorram O. Replacement of DHEA in aging men and women: potential remedial effects. Ann NY Acad Sci 1995;774:128–142.PubMedCrossRefGoogle Scholar
  101. 101.
    Jakubowicz D, Beer N, Rengifo R. Effect of dehydroepiandrosterone on cyclic-guanosine monophosphate in men of advancing age. Ann NY Acad Sci 1995;774:312–315.PubMedCrossRefGoogle Scholar
  102. 102.
    Bates GW Jr, Egerman RS, Umstor ES, Buster JE, Casson PR. Dehydroepiandrosterone attenuates study-induced declines in insulin sensitivity in postmenopausal women. Ann NY Acad Sci 1995;774:291–293.PubMedCrossRefGoogle Scholar
  103. 103.
    Wolkowitz OM, Reus VI, Roberts E, et al. Antidepressant and cognition: enhancing effects of DHEA in major depression. Ann NY Sci 1995;774:337–339.CrossRefGoogle Scholar
  104. 104.
    Morales AJ, Nolan JJ, Nelson JC, et al. Effects of replacement dose of dehydroepiandrosterone in men and women of advancing age. J Clin Endocrinol Metab 1994;78: 1360–1367.PubMedCrossRefGoogle Scholar
  105. 105.
    Kamel H, Kaiser FE. The menopause: clinical aspects and current trends in therapy. In: Vellas B, Albarede JL, Garry PJ (eds) Women, Aging and Health. Serdi: Paris, 1998:105–143.Google Scholar
  106. 106.
    Longcope C. Hormone dynamics at the menopause. Am J Obstet Gynecol 1980;13:564.Google Scholar
  107. 107.
    Utian WH. The place of estriol therapy after menopause. Acta Endocrinol Suppl (Copenh) 1980;233:51–56.Google Scholar
  108. 108.
    Kuller LH, Meilahn EN, Gutai J, et al. Lipoproteins, Estrogen, and the Menopause: Biological and Clinical Consequences of Ovarian Failure: Evolution and Management. Serono Symposia USA: Norwell, MA, 1990:179–197.Google Scholar
  109. 109.
    Sarrel PM, Lufkin EG, Ousler MJ, Keefe D. Estrogen actions in arteries, bone, and brain. Sci Am Sci Med 1994;1: 44–53.Google Scholar
  110. 110.
    Winner SJ, Morgan CA, Evans JG. Perimenopausal risk of falling and incidence of distal forearm fracture. BMJ 1989; 298:1486–1488.PubMedCrossRefGoogle Scholar
  111. 111.
    Paganini-Hill A, Henderson VW. Estrogen replacement therapy and risk of Alzheimer disease. Arch Intern Med 1996;28:156:2213–2217.CrossRefGoogle Scholar
  112. 112.
    Tabg MX, Jacobs D, Stern Y, et al. Effect of estrogen during menopause on risk and age at onset of Alzheimer’s disease. Lancet 1996;348:429–432.CrossRefGoogle Scholar
  113. 113.
    Lufkin EG, Riggs BL. Three-year follow-up on effects of transdermal estrogen [letter]. Ann Intern Med 1996;125: 77.PubMedCrossRefGoogle Scholar
  114. 114.
    Haines CJ, Chung TK, Masarei JR, et al. The effect of percutaneous estrogen replacement therapy on Lp(a) and other lipoproteins. Maturitas 1995;22:219–225.PubMedCrossRefGoogle Scholar
  115. 115.
    Walsh BW, Li H, Sacks FM. Effect of postmenopausal hormone replacement with oral and transdermal estrogens on high density lipoprotein metabolism. J Lipid Res 1994;35:2083–2089.PubMedGoogle Scholar
  116. 116.
    Whitehead MI, Townsend PT, Pryse-Davies J, et al. Effects of estrogens and progestins on the biochemistry and morphology of the postmenopausal endometrium. N Engl J Med 1981;305:1599–1605.PubMedCrossRefGoogle Scholar
  117. 117.
    Voigt LF, Eeiss CSC, Chu J, Dalling JR. Progestagens supplementation of exogenous estrogens and risk of endometrial cancer. Lancet 1991;338:274–277.PubMedCrossRefGoogle Scholar
  118. 118.
    Harris MI, Hadden WC, Knowler WC, et al. Prevalence of diabetes and impaired glucose tolerance and plasma glucose levels in US populations, ages 20–74 years. Diabetes 1987;36:523–534.PubMedCrossRefGoogle Scholar
  119. 119.
    Singh I, Marshall MC. Diabetes mellitus in the elderly. Endocrinol Metab Clin North Am 1995;24:255–272.PubMedGoogle Scholar
  120. 120.
    American Diabetes Association. Clinical practice recommendation 1998. Diabetes Care 1998;21(suppl 1):S1–S98.Google Scholar
  121. 121.
    Halter JB. Diabetes mellitus. In: Hazzard W, et al. (eds) Principles of Geriatric Medicine and Gerontology, 4th ed. McGraw-Hill: New York, 1998:991–1011.Google Scholar
  122. 122.
    American Diabetes Association. Nutritional principles for the management of diabetes and related complications [technical review]. Diabetes Care 1994;17:490–518.Google Scholar
  123. 123.
    American Diabetes Association. Nutritional recommendations and principles for people with diabetes mellitus [position statement]. Diabetes Care 1994;17:519–522.CrossRefGoogle Scholar
  124. 124.
    LeBlanc J, Nadeau A, Richard D, et al. Studies on the sparing effect of exercise on insulin requirements in human subjects. Metabolism 1981;30:1119–1124.PubMedCrossRefGoogle Scholar
  125. 125.
    Gerich JE. Oral hypoglycemic agents. N Engl J Med 1989;321:1231–1245.PubMedCrossRefGoogle Scholar
  126. 126.
    Fonseca VA, Valiquett TR, Huang SM, et al. Troglitazone monotherapy improves glycemic control in patients with type 2 diabetes mellitus: a randomized controlled study: the Troglitazone Study Group. J Clin Endocrinol Metab 1998;83:3169–3176.PubMedCrossRefGoogle Scholar
  127. 127.
    Neuschwander-Teri BA, Isley WL, Oki JC, et al. Troglita-zone-induced hepatic failure leading to liver transplantation: a case report. Ann Intern Med 1998;129:38–41.CrossRefGoogle Scholar
  128. 128.
    Watkins PB, Wintcomb RW. Hepatic dysfunction associated with troglitazone [letter]. N Engl J Med 1998;338: 916–917.PubMedCrossRefGoogle Scholar
  129. 129.
    Morley JE, Kaiser FE. Unique aspects of diabetes mellitus in the elderly. Clin Geriatr Med 1990;6:693–702.PubMedGoogle Scholar
  130. 130.
    Kerson CM, Baile GR. Do diabetic patients inject accurate doses of insulin? Diabetes Care 1981;4: 333–337.Google Scholar
  131. 131.
    Peters AL, Davidson MB. Insulin plus a sulfonylurea agent for treating type 2 diabetes. Ann Intern Med 1991;115: 45–53.PubMedCrossRefGoogle Scholar
  132. 132.
    Morley JE, Kaiser FE. Unique aspects of diabetes mellitus in the elderly. Clin Geriatr Med 1990;6:693–702.PubMedGoogle Scholar
  133. 133.
    Hornick T, Kowal J. Endocrine disorders in the elderly. In: Jahnigen DW, Schrier RW (eds) Geriatric Medicine, 2nd ed. Blackwell Science: Boston, 1996:754–767.Google Scholar
  134. 134.
    Maheshwari H, Sharma L, Baumann G. Decline of plasma growth hormone binding protein in old age. J Clin Endocrinol Metab 1996;81:995–997.PubMedCrossRefGoogle Scholar
  135. 135.
    Vermeulen A. Nyctohemeral growth hormone profiles in young and aged men: correlation with somatomedin C levels. J Clin Endocrinol Metab 1987;64:884.PubMedCrossRefGoogle Scholar
  136. 136.
    Rudman D, Feller AG, Cohn L. Effects of human growth hormone binding protein in old age. J Clin Endocrinol Metab 1996;81:995–997.CrossRefGoogle Scholar
  137. 137.
    Kaiser FE, Silver AJ, Morley JE. The effect of recombinant human growth hormone on malnourished older individuals. J Am Geriatr Soc 1991;39:235–240.PubMedGoogle Scholar
  138. 138.
    Cohn L, Feller AG, Draper MW, et al. Carpal tunnel syndrome and gynecomastia during human growth hormone treatment of elderly men with low circulation IGF-1. Clin Endocrinol (Oxf) 1993;39:417–425.CrossRefGoogle Scholar
  139. 139.
    Wolfsen AR. Aging and the adrenals. In: Korenman SG (ed) Endocrine Aspects of Aging. Elsevier-North Holland: New York, 1982:55–74.Google Scholar
  140. 140.
    Tuck ML, Williams GM, Cain JR, Relation of age, diastolic pressures and known duration of hypertension to presence of low renin essential hypertension. Am J Cardiol 1973; 32:632–637.CrossRefGoogle Scholar

Copyright information

© Springer Science+Business Media New York 2001

Authors and Affiliations

  • Hosam K. Kamel
  • John E. Morley

There are no affiliations available

Personalised recommendations